DI-1548 是一种强效、选择性、不可逆的 DCN1 共价抑制剂(IC50 = 4.6 nM),能在纳摩尔浓度下强效且选择性地抑制 Cullin 3 的 neddylation 修饰,对其它 Cullin 蛋白(包括 Cullin 1、2、4A、4B 和 5)的 neddylation 过程无明显影响,且无细胞毒性;其与 DCN1 的共价结合会破坏 DCN1-UBC12 相互作用,导致 neddylation 复合物崩解,进而使 CRL3 失活,最终导致 NRF2 积累及其靶基因上调,从而在小鼠模型中起到保护肝脏的作用,可用于肝损伤相关研究。
产品编号: MS-X83212 CAS No.: 2247060-97-3 分子式: C32H47N5O4S 分子量: 597.81
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

DI-1548 是一种强效、选择性、不可逆的 DCN1 共价抑制剂(IC50 = 4.6 nM),能在纳摩尔浓度下强效且选择性地抑制 Cullin 3 的 neddylation 修饰,对其它 Cullin 蛋白(包括 Cullin 1、2、4A、4B 和 5)的 neddylation 过程无明显影响,且无细胞毒性;其与 DCN1 的共价结合会破坏 DCN1-UBC12 相互作用,导致 neddylation 复合物崩解,进而使 CRL3 失活,最终导致 NRF2 积累及其靶基因上调,从而在小鼠模型中起到保护肝脏的作用,可用于肝损伤相关研究。

生物实验数据

生物活性 DI-1548 is a potent, selective, and irreversible covalent inhibitor of DCN1 (IC50 = 4.6 nM) that potently and selectively inhibits Cullin 3 neddylation at nanomolar concentrations without significantly affecting the neddylation of other Cullin proteins (including Cullin 1, 2, 4A, 4B, and 5) and without cytotoxicity; its covalent binding to DCN1 disrupts the DCN1-UBC12 interaction, leading to disassembly of the neddylation complex, thereby inactivating CRL3 and ultimately resulting in NRF2 accumulation and upregulation of its target genes, which confers liver protection in mouse models, making it useful for research on liver injury.
体外研究
(In Vitro)

DI-1548 (1-1000 nM,24 小时) 在 U2OS 细胞中,在低至 1 nM 的浓度下即可抑制 cullin 3 的 neddylation 修饰,其效力比 DI-591 (MS-M27170) 强约 1000 倍。
DI-1548 (0.3-1000 nM,24 小时) 在多种细胞系 (包括 U2OS、 MDA-MB-231、 KYSE70 和 HCT116) 中,能抑制 Cullin 3 的 neddylation 修饰,且对其他 Cullin 蛋白成员的选择性超过 1000 倍。
DI-1548 (0-1000 nM,72 小时) 在浓度高达 1000 nM 时,对 U2OS、 MDA-MB-231、 HCT116 和 KYSE70 细胞均无细胞毒性。
DI-1548 (30 nM,0-48 小时) 能快速且持久地选择性抑制 Cullin 3 (而非 Cullin 1) 的 neddylation 修饰。
DI-1548 (0.3-1000 nM,1 小时) 在纳摩尔浓度下以剂量依赖性方式选择性地强效稳定细胞内的 DCN1 蛋白,对 DCN3 无明显影响。

Western Blot Analysis

Cell Line: U2OS cells
Concentration: 1, 10, 100 and 1000 nM
Incubation Time: 24 h
Result: Reduced N-Cul3 levels at 1 nM and was approximately 1000 times more potent than DI-591.

Western Blot Analysis

Cell Line: U2OS, MDA-MB-231, HCT116 and KYSE70 cells
Concentration: 0.3, 1, 3, 10, 30, 100, and 1000 nM
Incubation Time: 24 h
Result: Significantly reduced the level of N-CUL3 at concentrations as low as 0.3 nM, and achieved profound inhibition of the neddylation of cullin 3 at 1-3 nM.
Demonstrate over 300-fold greater potency than DI-591 across various cell lines.
Had no obvious effect on the neddylation of other cullin members that were examined, including cullin 1, 2, 4A, 4B, and 5 at concentrations up to 1000 nM.
Induced significant accumulation of NRF2 protein at concentrations as low as 0.3-1 nM, and was 100-1000 times more potent than DI-591.
Had no obvious effect on protein levels of KEAP1 and p62 in U2OS cells.
Had no effect on the levels of p21 and BIM proteins, substrates of CRL1, and CDT1, a substrate of CRL4A, at concentrations up to 1000 nM, consistent with its inability to inhibit neddylation of these cullin members.

Cell Viability Assay

Cell Line: U2OS, MDA-MB-231, HCT116 and KYSE70 cells
Concentration: 0-1000 nM
Incubation Time: 72 h
Result: Showed no cytotoxicity in four cancer cell lines at concentrations up to 1000 nM.

Western Blot Analysis

Cell Line: U2OS cells
Concentration: 30 nM
Incubation Time: 5 and 30 min,6, 24, and 48 h
Result: Inhibited the neddylation of cullin 3 within 5min but had no effect on the neddylation of cullin 1 with treatment time up to 48 h.

Western Blot Analysis

Cell Line: U2OS cells
Concentration: 0.3, 1, 3, 10, 30, 100, and 1000 nM
Incubation Time: 1 h
Result: Enhanced the thermal stability of DCN1 protein in a dose-dependent manner at concentrations as low as 0.3 nM.
Exhibited over 1000-fold greater potency than DI-591 in enhancing the thermal stability of cellular DCN1 protein.
Showed no discernible effect on the thermal stability of cellular DCN3 protein at concentrations up to 1000 nM.
体内研究
(In Vivo)

DI-1548 (25 mg/kg,腹腔注射,单次给药) 可升高 C57BL/6 野生型小鼠肝脏中的 NRF2 蛋白水平。

Animal Model: Male C57BL/6 WT mice (~8 weeks)
Dosage: 25 mg/kg
Administration: i.p., once
Result: Induced robust upregulation of NRF2 protein in the mouse liver.
Produced a sustained PD effect in the liver despite being cleared from systemic circulation within 3 hours.

化学信息

分子量 597.81
分子式 C32H47N5O4S
CAS No. 2247060-97-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础